Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis by Serfaty, L, Lemoine, M

Get full text

Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives by Serfaty, L, Poupon, R

Get full text

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C by Fartoux, L, Poujol-Robert, A, Guéchot, J, Wendum, D, Poupon, R, Serfaty, L

Get full text

873 PROGRESSION OF NAFLD IN HUMANS IS ASSOCIATED WITH THE ACTIVATION OF THE RENIN-ANGIOTENSIN SYSTEM by Vergniol, J, Barbu, V, Lemoine, M, Wendum, D, Chatzantoniou, C, Serfaty, L, Housset, C, Ratziu, V

Get full text

Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries by Younossi, Z., Brown, A., Buti, M., Fagiuoli, S., Mauss, S., Rosenberg, W., Serfaty, L., Srivastava, A., Smith, N., Stepanova, M., Beckerman, R.

Get full text

Toxic hepatitis induced by a herbal medicine: Tinospora crispa by Langrand, J., Regnault, H., Cachet, X., Bouzidi, C., Villa, A.F., Serfaty, L., Garnier, R., Michel, S.

Get full text

Acceptance and commitment therapy for late-life treatment-resistant generalised anxiety disorder: a feasibility study by Gould, Rebecca L, Wetherell, Julie Loebach, Kimona, Kate, Serfaty, Marc A, Jones, Rebecca, Graham, Christopher D, Lawrence, Vanessa, Livingston, Gill, Wilkinson, Philip, Walters, Kate, Le Novere, Marie, Leroi, Iracema, Barber, Robert, Lee, Ellen, Cook, Jo, Wuthrich, Viviana M, Howard, Robert J

Get full text

Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis by Ratziu, V, Sanyal, A, Torres, D, Hinrichsen, H, Serfaty, L, Bambha, K, Jayakumar, S, Goodman, Z, Abdelmalek, M, Aguilar, R, Jia, C, Mccolgan, B, Myers, R, Subramanian, M, McHutchison, J, Afdhal, N, Harrison, S

Get full text

Hepatic fibrosis is associated with histological activity in nonalcoholic steatohepatitis: an analysis from a large database of screening biopsies in the CENTAUR trial by Ratziu, V, Wong, V.W.-S, Lanthier, N, Boursier, J, Alazawi, W, Kluwe, J, Genesca, J, Andreone, P, Serfaty, L, Skoien, R, Wiens, B.L, Vig, P, Lefebvre, E, Seyedkazemi, S, Kayali, Z, Poordad, F, Sanyal, A, Tacke, F, Goodman, Z

Get full text

Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistance by Lemoine, M., Chevaliez, S., Bastard, J. P., Fartoux, L., Chazouillères, O., Capeau, J., Pawlotsky, J. M., Serfaty, L.

Get full text

Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients by Loko, M.-A., Bani-Sadr, F., Winnock, M., Lacombe, K., Carrieri, P., Neau, D., Morlat, P., Serfaty, L., Dabis, F., Salmon, D.

Get full text

O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial by Bourliere, M, Rabiega, P, Ganne-Carrie, N, Serfaty, L, Marcellin, P, Pouget, N, Guyader, D, Hezode, C, Picon, M, Causse, X, Leroy, V, Bronowicki, J.P, Riachi, G, Rosa, I, Attali, P, Molina, J.M, Bacq, Y, Tran, A, Grangé, J.D, Zoulim, F, Fontaine, H, Bertucci, I, Bouvier-Alias, M, Carrat, F, Benhamou, Y

Get full text

Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus by Boyd, A., Lacombe, K., Miailhes, P., Gozlan, J., Bonnard, P., Molina, J.-M., Lascoux-Combe, C., Serfaty, L., Gault, E., Desvarieux, M., Girard, P.-M.

Get full text

P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic by Bronowicki, J.-P, Fontaine, H, Dufour, C, Zoulim, F, Larrey, D, Canva, V, Samuel, D, Poynard, T, Marcellin, P, De Ledinghen, V, Bourlière, M, Alric, L, Zarski, J.-P, Raabe, J.-J, Serfaty, L, Metivier, S, Riachi, G, Abergel, A, Loustaud-Ratti, V, Causse, X, Guyader, D, Bernard, P.-H, Attali, P, Di Martino, V, Cacoub, P, Cales, P, Tran, A, Rosa, I, Grando-Lemaire, V, Portal, I, Dao, T, Lucidarme, D, Fontanges, T, Barthe, Y, Pawlotsky, J.-M, Pol, S, Carrat, F, Hezode, C

Get full text

888 SAFETY AND TOLERABILITY OF TELAPREVIR-BASED TRIPLE THERAPY IN HIV/HCV COINFECTED VERSUS HCV MONOINFECTED PATIENTS IN “REAL LIFE”: A MATCHED-COHORT STUDY by Pascale, A, Boyd, A, Bottero, J, Stitou, H, Valin, N, Benjelloun, F, Chazouillères, O, Girard, P.-M, Serfaty, L, Lacombe, K

Get full text

739 ALT FLARES DURING TREATMENT WITH PEGINTERFERON LAMBDA OR PEGINTERFERON alfa IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B INFECTION (CHB) by Chan, H.L, Ahn, S.H, Chang, T.-T, Peng, C.-Y, Wong, D, Coffin, C, Lim, S.G, Chen, P.-J, Janssen, H.L, Marcellin, P, Serfaty, L, Zeuzem, S, Hu, W, Critelli, L, Wind-Rotolo, M, Srinivasan, S, Lopez-Talavera, J.C, Cooney, E

Get full text

Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer by Parc, Y, Gueroult, S, Mourra, N, Serfaty, L, Fléjou, J-F, Tiret, E, Parc, R

Get full text

High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after hav... by Serfaty, L, Pianko, S, Ari, Z.B, Laursen, A.L, Hansen, J, Gane, E.J, Huang, H.-C, Jin, S, Bourque, J, Liu, H, Grandhi, A, Su, M, Gendrano, N, Fernsler, D, Dutko, F, Nguyen, B.-Y.T, Wahl, J, Barr, E, Yeh, W, Plank, R, Butterton, J.R

Get full text